

Research Article

The Diagnostic and Prognostic Values of C-Reactive Protein and Procalcitonin during Bacterial Infections in Decompensated Cirrhosis

Sana Khedher,^{1,2} Nasreddine Fouthaili,^{1,2} Amira Maoui,^{2,3} Sirine Lahiani,^{2,3} Mohamed Salem,^{1,2} and Kahena Bouzid^{2,3,4}

¹Intensive Care Unit-Hepato and Gastroenterology Department, Charles Nicolle Hospital, Tunis, Tunisia ²Faculty of Medicine, University of Tunis El Manar, El Manar, Tunisia

³Laboratory of Clinical Biochemistry, Charles Nicolle Hospital, Tunis, Tunisia

⁴LR18ES03, Laboratory of Neurophysiology, Cellular Physiopathology and Biomolecules Valorisation, University of Tunis, El Manar 2092, Tunis, Tunisia

Correspondence should be addressed to Sana Khedher; sanakhedher@hotmail.fr

Received 12 September 2018; Accepted 25 November 2018; Published 30 December 2018

Academic Editor: Hauke S. Heinzow

Copyright © 2018 Sana Khedher et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Bacterial infection (BI) represents the main cause of decompensation and death in cirrhotic patients. Procalcitonin (PCT) and C-reactive protein (CRP) are two widely used biomarkers that may be helpful for early detection of BI especially in the presence of inflammation. Their accuracy for the diagnosis of BI in patients with chronic liver disease has been a subject of debate. In this study, we aimed to learn whether PCT and CRP would be helpful as early markers of BI in patients with cirrhosis and to evaluate their prognostic value in terms of mortality. *Subjects and Methods.* We retrospectively included 92 adult patients with decompensated cirrhosis. PCT and CRP plasma levels were obtained within the first 24 hours of admission. Their diagnostic and prognostic values were compared using the appropriate statistical analysis. *Results.* Ninety-two patients were included. BI was diagnosed in 60 patients (65%). Mean white blood cell (WBC) count (p = 0.005) and PCT and CRP serum levels (p < 0.001) were higher in the BI group than in the non-BI (NBI) group. The diagnostic accuracy of CRP and PCT for the diagnosis of BI was better than that of WBC. CRP was the most sensitive marker (70%) while PCT was the more specific (96.6%). No one of those biomarkers was predictive of 3-month mortality in patients with BI. *Conclusion.* Regarding BI in patients with decompensated cirrhosis, CRP maintains efficiency slightly higher than that of the PCT without being discriminative. However, no prognostic value has been established for these markers.

1. Introduction

Cirrhosis is the advanced stage of a liver condition due to a chronic inflammatory and fibrosing prolonged evolving process. Cirrhotic patients are more susceptible to bacterial infection (BI) because of humeral and cellmediated immunodeficiency, splanchnic ganglia colonization, bacterial translocation phenomena, and ventilatory disorders related to encephalopathy and ascites [1, 2]. BI is diagnosed in 30 to 50% of admitted cirrhotic versus 5 to 7% in noncirrhotic patients [3]. The diagnosis of BI in patients with cirrhosis is made difficult by some clinical and biological abnormalities commonly observed in those patients such as liver dysfunction, inflammation, chronic hypersplenism, abdominal distension, and neurological disorders in addition to the frequent use of betablockers. Despite the great improvement of BI management in cirrhotics, the mortality is still high. An early diagnosis and treatment of this condition, using biomarkers such as procalcitonin (PCT) and C-reactive protein (CRP), can contribute to reduce this mortality. This work is aimed at evaluating and comparing diagnosis and prognosis performance of CRP and PCT during BI in patients admitted for decompensated cirrhosis.

2. Methods

This 14-month observational retrospective study was conducted in the Hepato-gastroenterology Department of the Charles Nicolle University Hospital of Tunis from 01 September 2015 to 30 October 2016. We included patients admitted for decompensate cirrhosis. Cirrhosis was diagnosed according to histological and/or clinical, biological, and ultrasound findings suggesting portal hypertension and hepatocellular insufficiency. Decompensated cirrhosis was defined by the presence of ascites, jaundice, variceal hemorrhage, or hepatic encephalopathy. Patients not included in the study were those who were receiving intravenous antibiotics and those who were suffering from a systemic disease or a cancer including hepatocellular carcinoma. CRP and PCT are part of the routine biological sample performed at admission; we did not have to get patients' consent. The following severity and prognostic scores were used in our study: APACHE II score [4], Child-Turcotte-Pugh (CP) criteria [5], Model for End-Stage Liver Disease score (MELD) [6], CLIF-sequential organ failure assessment score (CLIF-SOFA), and Acute-on-chronic liver failure (ACLF) [7]. Blood samples for biological marker analysis as well as microbiological samples were obtained on admission. Serum CRP levels were measured using direct immunoturbidimetry on the Architect C 8000 Chemistry System (Abbott Diagnostics, USA). Enzyme-linked fluorescent immunoassay (ELFA) on mini-VIDAS (bioMérieux, France) was used for PCT tests. The patients were divided into a BI group and a non-BI (NBI) group. Dichotomous variables were expressed as percentages and continuous variables as mean ± standard deviation. Statistical comparisons were performed using, respectively, Student's t-test and χ^2 . Analysis of receiver operating characteristic (ROC) curves was used to determine diagnostic accuracy, sensitivity, and specificity and the Youden index to determine suggested cutoff. All analyses were conducted by SPSS 20.0 (SPSS Inc., Chicago, IL, USA). A p value of <0.05 was considered significant. Threemonth mortality risk factors were determined by the application of multivariate logistic regression analysis. The authors state the absence of conflict of interest.

3. Results

Ninety-two patients were included with a sex ratio of 0.96 and a mean age of 63 ± 13 years (19-91). Mean follow-up time was 4.5 ± 4 years (3 months-26 years). Fifty-seven patients (61%) were CP class B and 32% class C. Hepatitis C was the most common etiology of cirrhosis (42%). They were mainly admitted for edemato-ascitic decompensation and the main source of infection was pulmonary tract infection (62%) and spontaneous bacterial peritonitis (23%). Baseline characteristics, cirrhosis etiologies, causes for admission, infection sources, and severity scores are summarized in Table 1. Distributions of sex, age, and comorbidities were similar between the two groups (Table 2). BI group had significantly higher encephalopathy rate (p = 0.005), higher total serum bilirubin level (p = 0.021), higher international

TABLE 1: Baseline characteristics of patients.

Number of patients	92
Mean age, years	63 ± 13 (19-91)
Male, n	45
Female, n	47
Cirrhosis etiology, n (%)	
Hepatitis C	39 (42)
Hepatitis B	9 (10)
Autoimmune hepatitis	7 (8)
Primary biliary cirrhosis	8 (9)
Alcohol	3 (4)
Nonalcoholic steatohepatitis	7 (8)
Cryptogenic	13 (14)
Others	4 (5)
Causes for admission, n (%)	
Edemato-ascitic decompensation	46 (50)
Hepatic encephalopathy	23 (25)
Gastro-intestinal bleeding	14 (15)
Fever	14 (15)
Others	9 (10)
Infection source, n (%)	
Pulmonary tract infection	37 (62)
Urinary tract infection	12 (20)
Spontaneous bacterial peritonitis	14 (23)
Skin infection	5 (8)
Multiple sites	6 (10)
Bacteremia	9 (14)
Isolated	3 (5)
Associated to another source	6 (10)
Severity scores	
Child-Pugh class (%)	
А	7
В	61
С	32
Child-Pugh, mean	$10 \pm 2 (6-15)$
ACLF (%)	
Grade 1	33
Grade 2	32
Grade 3	35
MELD score, mean	$18 \pm 7 (8-35)$
APACHE II score, mean	20 + 5(12 - 34)

MELD: Model for End-Stage Liver Disease; APACHE II: Acute Physiology and Chronic Health Disease Classification System II; ACLF: Acute-onchronic liver failure.

normalized ratio (p = 0.005), lower prothrombin time (p = 0.005), and higher MELD score (p < 0.01). Mean serum levels of CRP (p < 0.001), PCT (p < 0.001), and white blood cells (WBC) (p = 0.002) were significantly higher in the BI group than in the NBI group (Table 2). The results of the logistic regression analysis showed that only MELD score > 15,

Age (yr) 60 ± 12 64 ± 15 0.509 Male/female $30/30$ $15/17$ 0.775 Medical historyDiabetes mellitus 38% 44% 0.614 Hypertension 28% 19% 0.350 Alcoholism 15% 13% 0.786 Child-Pugh (class) X X 0.786 A 1% 6% 0.123 B 28% 44% 0.256 C 70% 50% 0.456 MELD score 20 ± 7 15 ± 5 $<.001$ APACHE II score 13 ± 8 15 ± 6 0.855 CLIF-SOFA score 15 ± 6 16 ± 6 0.757 Grade 1 32% 38% 0.609 Grade 2 33% 28% 0.609 Grade 3 34% 34% 0.952 Duration of stay (d) 12 ± 8 12 ± 6 0.766 3-month mortality 34% 3% 0.008 Vital signsBody temperature 08 ± 0.7 37 ± 0.5 0.008 Heart rate 97 ± 15 85 ± 18 0.025 Respiratory rate 108 ± 21 111 ± 20 0.393 pressure (mm Hg) 108 ± 21 111 ± 20 0.393 Diastolic blood pressure (mm Hg) 62 ± 13 66 ± 10 0.193 Encephalopathy 72% 37% 0.002 Neutrophil (cells/IL) 6430 ± 4456 3668 ± 2151 0.001 Neutrophil (cells/IL) $16505 5672 \pm 2734$ 0.002 Serum BUN (mm		Bacterial infection group n = 60	Nonbacterial infection group n = 32	<i>p</i> value
Nale/female $30/30$ $15/17$ 0.775 Medical historyDiabetes mellitus 38% 44% 0.614 Hypertension 28% 19% 0.350 Alcoholism 15% 13% 0.786 Child-Pugh (class) 15% 13% 0.786 A 1% 6% 0.123 B 28% 44% 0.256 C 70% 50% 0.456 MELD score 20 ± 7 15 ± 5 $<.001$ APACHE II score 13 ± 8 15 ± 6 0.855 CLIF-SOFA score 15 ± 6 16 ± 6 0.757 ACLFGrade 1 32% 38% 0.609 Grade 2 33% 28% 0.609 Grade 3 34% 34% 0.952 Duration of stay (d) 12 ± 8 12 ± 6 0.766 3-month mortality 34% 3% 0.008 Vital signs $Vita$ 8 ± 0.7 37 ± 0.5 0.008 Heart rate (beats/min) 97 ± 15 85 ± 18 0.252 Pressure (mm Hg) 108 ± 21 111 ± 20 0.393 Diastolic blood pressure (mm Hg) 62 ± 13 66 ± 10 0.193 Diastolic blood pressure (mm Hg) 105056 ± 80901 91000 ± 42063 0.361 Neutrophil (cells/IL) 6430 ± 4456 366 ± 2151 0.002 Neutrophil (cells/IL) 105056 ± 80901 91000 ± 42063 0.361 Platelet (cells/IL) 105056 ± 80901 91000 ± 42063 0.361 Platelet (cells/IL) 7.4 ± 5.9 <t< td=""><td>Age (yr)</td><td>60 ± 12</td><td>64 ± 15</td><td>0.509</td></t<>	Age (yr)	60 ± 12	64 ± 15	0.509
Medical historyNumber of the second sec	Male/female	30/30	15/17	0.775
Diabetes mellitus 38% 44% 0.614 Hypertension 28% 41% 0.231 Tabagism 28% 19% 0.350 Alcoholism 15% 13% 0.786 Child-Pugh (class) x x x A 1% 6% 0.123 B 28% 44% 0.256 C 70% 50% 0.456 MELD score 20 ± 7 15 ± 5 <001 APACHE II score 13 ± 8 15 ± 6 0.855 CLIF-SOFA score 15 ± 6 16 ± 6 0.757 Grade 1 32% 38% 0.573 Grade 2 33% 28% 0.6952 Duration of stay (d) 12 ± 8 12 ± 6 0.766 3-mont mortality 34% 3% 0.008 Vital signs $g7 \pm 15$ 85 ± 18 0.025 Body temperature (°C) 38 ± 0.7 37 ± 0.5 0.008 Heart rate (beats/min) 97 ± 15 85 ± 18 0.251 Systolic blood pressure (mm Hg) 108 ± 21 111 ± 20 0.393 Diatolic blood pressure (mm Hg) 62 ± 13 66 ± 10 0.193 Ascite 85% 84% 0.647 WBCs (cells/IL) 105056 ± 80901 91000 ± 42063 0.361 Varidy 8.8 ± 5.2 7.4 ± 5.9 0.282 Ferum BUN (mmol/L) 8.8 ± 5.2 7.4 ± 5.9 0.282 ALT (U/L) 78 ± 106 56 ± 38 0.350 ALT (U/L) 7	Medical history			
Hypertension28%41%0.231Tabagism28%19%0.350Alcoholism15%13%0.786Child-Pugh (class)A1%6%0.123B28%44%0.256C70%50%0.456MELD score20 \pm 715 \pm 5<.001	Diabetes mellitus	38%	44%	0.614
Tabagism 28% 19% 0.350 Alcoholism 15% 13% 0.786 Child-Pugh (class) 11% 6% 0.123 B 28% 44% 0.256 C 70% 50% 0.456 MELD score 20 ± 7 15 ± 5 $<.001$ APACHE II score 13 ± 8 15 ± 6 0.855 CLIF-SOFA score 15 ± 6 16 ± 6 0.757 ACLF $Grade 1$ 32% 38% 0.573 Grade 1 32% 38% 0.609 Grade 3 34% 34% 0.952 Duration of stay (d) 12 ± 8 12 ± 6 0.766 3-month mortality 34% 3% 0.008 Vital signs $Vital$ 0.7 ± 0.5 0.008 Body temperature 07 ± 15 85 ± 18 0.25 Heart rate 97 ± 15 85 ± 18 0.25 (breaths/min) 21 ± 4 20 ± 5 0.189 pressure (mm Hg) 108 ± 21 111 ± 20 0.393 Diastolic blood pressure (mm Hg) 62 ± 13 66 ± 10 0.193 Ascite 85% 84% 0.647 WBCs (cells/IL) 630 ± 4456 3668 ± 2151 0.001 Platelet (cells/IL) 105056 ± 80901 9100 ± 42063 0.361 Serum BUN (mmol/L) 8.8 ± 5.2 7.4 ± 5.9 0.282 Grade 10 116 ± 101 90 ± 51 0.167 ALT (IU/L) 78 ± 106 56 ± 38 0.350 ALT (IU/L) </td <td>Hypertension</td> <td>28%</td> <td>41%</td> <td>0.231</td>	Hypertension	28%	41%	0.231
Alcoholism15%13%0.786Child-Pugh (class)A1%6%0.123B28%44%0.256C70%50%0.456MELD score 20 ± 7 15 ± 5 <.001	Tabagism	28%	19%	0.350
Child-Pugh (class) A 1% 6% 0.123 B 28% 44% 0.256 C 70% 50% 0.456 MELD score 20 ± 7 15 ± 5 <.001	Alcoholism	15%	13%	0.786
A1%6%0.123B28%44%0.256C70%50%0.456MELD score 20 ± 7 15 ± 5 <.001	Child-Pugh (class)			
B 28% 44% 0.256 C 70% 50% 0.456 MELD score 20 ± 7 15 ± 5 <.001	А	1%	6%	0.123
C70%50%0.456MELD score 20 ± 7 15 ± 5 <.001APACHE II score 13 ± 8 15 ± 6 0.855CLIF-SOFA score 15 ± 6 16 ± 6 0.757ACLF777Grade 1 32% 38% 0.609Grade 2 33% 28% 0.609Grade 3 34% 34% 0.952Duration of stay (d) 12 ± 8 12 ± 6 0.7663-month mortality 34% 3% 0.008Vital signs80dy temperature (°C) 38 ± 0.7 37 ± 0.5 0.008Body temperature (beats/min) 97 ± 15 85 ± 18 0.025Respiratory rate (breaths/min) 21 ± 4 20 ± 5 0.189Diastolic blood pressure (mm Hg) 08 ± 21 111 ± 20 0.393Diastolic blood pressure (mm Hg) 62 ± 13 66 ± 10 0.193 Encephalopathy 72% 37% 0.002 Neutrophil (cells/IL) 6430 ± 4456 3668 ± 2151 0.001 Platelet (cells/IL) 105056 ± 80901 91000 ± 42063 0.361 Serum BUN (mon/L) 8.8 ± 5.2 7.4 ± 5.9 0.282 Serum BUN (mmO/L) 8.8 ± 5.2 7.4 ± 5.9 0.282 ALT (IU/L) 78 ± 106 56 ± 38 0.350 ALT (IU/L) 78 ± 106 56 ± 38 0.350 ALT (IU/L) 78 ± 106 56 ± 38 0.350 ALT (IU/L) 78 ± 106 56 ± 38 0.351 AL	В	28%	44%	0.256
MELD score 20 ± 7 15 ± 5 <0.011 APACHE II score 13 ± 8 15 ± 6 0.855 CLIF-SOFA score 15 ± 6 16 ± 6 0.757 ACLF </td <td>С</td> <td>70%</td> <td>50%</td> <td>0.456</td>	С	70%	50%	0.456
$\begin{array}{llllllllllllllllllllllllllllllllllll$	MELD score	20 ± 7	15 ± 5	<.001
CLIF-SOFA score 15 ± 6 16 ± 6 0.757 ACLFGrade 1 32% 38% 0.573 Grade 2 33% 28% 0.609 Grade 3 34% 34% 0.952 Duration of stay (d) 12 ± 8 12 ± 6 0.766 3 -month mortality 34% 3% 0.008 Vital signs 80 5 ± 18 0.025 Body temperature 38 ± 0.7 37 ± 0.5 0.008 (°C) 38 ± 0.7 37 ± 0.5 0.008 (beats/min) 97 ± 15 85 ± 18 0.025 Respiratory rate 21 ± 4 20 ± 5 0.189 (breaths/min) 108 ± 21 111 ± 20 0.393 pressure (mm Hg) 62 ± 13 66 ± 10 0.193 pressure (mm Hg) 72% 37% 0.005 Ascite 85% 84% 0.647 WBCs (cells/IL) 8750 ± 5005 5672 ± 2734 0.002 Neutrophil (cells/IL) 6430 ± 4456 3668 ± 2151 0.001 Platelet (cells/IL) 105056 ± 80901 91000 ± 42063 0.361 Serum BUN (mmol/L) 8.8 ± 5.2 7.4 ± 5.9 0.282 ALT (IU/L) 78 ± 106 56 ± 38 0.350 ALT (IU/L) 78 ± 106 56 ± 38 0.350 ALT (IU/L) 48 ± 18 58 ± 16 0.007 INR 1.91 ± 0.64 1.55 ± 0.36 0.021 INR 1.91 ± 0.64 1.55 ± 0.57 0.572	APACHE II score	13 ± 8	15 ± 6	0.855
ACLFGrade 132%38%0.573Grade 233%28%0.609Grade 334%34%0.952Duration of stay (d)12 ± 812 ± 60.7663-month mortality34%3%0.008Vital signs 3 ± 0.7 37 ± 0.5 0.008Heart rate (beats/min) 97 ± 15 85 ± 18 0.025Respiratory rate (breaths/min) 21 ± 4 20 ± 5 0.189Systolic blood pressure (mm Hg) 108 ± 21 111 ± 20 0.393Diastolic blood pressure (mm Hg) 62 ± 13 66 ± 10 0.193Ascite85%84%0.647WBCs (cells/IL) 6430 ± 4456 3668 ± 2151 0.002Neutrophil (cells/IL) 10505 ± 80901 91000 ± 42063 0.361Platelet (cells/IL) 10505 ± 80901 91000 ± 42063 0.361Serum BUN (mmol/L) 8.8 ± 5.2 7.4 ± 5.9 0.282AST (IU/L) 78 ± 106 56 ± 38 0.350ALT (IU/L) 43 ± 55 40 ± 55 0.803Total bilirubin (mg/L) 102 ± 137 43 ± 45 0.021INR 1.91 ± 0.64 1.55 ± 0.36 0.007INR 1.91 ± 0.64 1.55 ± 0.57 0.572	CLIF-SOFA score	15 ± 6	16 ± 6	0.757
Grade 132%38%0.573Grade 233%28%0.609Grade 334%34%0.952Duration of stay (d) 12 ± 8 12 ± 6 0.7663-month mortality34%3%0.008Vital signs 34% 3%0.008Vital signs 97 ± 15 85 ± 18 0.025Meart rate (beats/min) 97 ± 15 85 ± 18 0.025Respiratory rate (breaths/min) 21 ± 4 20 ± 5 0.189Systolic blood pressure (mm Hg) 108 ± 21 111 ± 20 0.393Diastolic blood pressure (mm Hg) 62 ± 13 66 ± 10 0.193Encephalopathy 72% 37% 0.005Ascite 85% 84% 0.647WBCs (cells/IL) 6430 ± 4456 3668 ± 2151 0.011Platelet (cells/IL) 105056 ± 80901 91000 ± 42063 0.361Serum BUN (mmol/L) 8.8 ± 5.2 7.4 ± 5.9 0.282Serum BUN (mmol/L) 78 ± 106 56 ± 38 0.350ALT (IU/L) 78 ± 106 56 ± 38 0.350ALT (IU/L) 43 ± 55 40 ± 55 0.803Total bilirubin (mg/L) 102 ± 137 43 ± 45 0.021INR 1.91 ± 0.64 1.55 ± 0.36 0.005Albumin (g/L) 25 ± 5 26 ± 5 0.579	ACLF			
Grade 233%28%0.609Grade 334%34%0.952Duration of stay (d) 12 ± 8 12 ± 6 0.7663-month mortality34%3%0.008Vital signs 34% 37% 0.008Body temperature (°C) 38 ± 0.7 37 ± 0.5 0.008Heart rate (beats/min) 97 ± 15 85 ± 18 0.025Respiratory rate (breaths/min) 21 ± 4 20 ± 5 0.189Systolic blood pressure (mm Hg) 108 ± 21 111 ± 20 0.393Diastolic blood pressure (mm Hg) 62 ± 13 66 ± 10 0.193Encephalopathy 72% 37% 0.005Ascite 85% 84% 0.647WBCs (cells/IL) 6430 ± 4456 3668 ± 2151 0.011Platelet (cells/IL) 105056 ± 80901 91000 ± 42063 0.361Serum BUN (mmol/L) 8.8 ± 5.2 7.4 ± 5.9 0.282Serum Creatinine ($\mu mol/L$) 116 ± 101 90 ± 51 0.167ALT (IU/L) 78 ± 106 56 ± 38 0.350ALT (IU/L) 43 ± 55 40 ± 55 0.803Total bilirubin (mg/L) 102 ± 137 43 ± 45 0.021INR 1.91 ± 0.64 1.55 ± 0.36 0.005Albumin (g/L) 25 ± 5 26 ± 5 0.579	Grade 1	32%	38%	0.573
Grade 3 34% 34% 0.952 Duration of stay (d) 12 ± 8 12 ± 6 0.766 3-month mortality 34% 3% 0.008 Vital signs 34% 37 ± 0.5 0.008 Body temperature (°C) 38 ± 0.7 37 ± 0.5 0.008 Heart rate (beats/min) 97 ± 15 85 ± 18 0.025 Respiratory rate (breaths/min) 21 ± 4 20 ± 5 0.189 Systolic blood pressure (mm Hg) 108 ± 21 111 ± 20 0.393 Diastolic blood pressure (mm Hg) 62 ± 13 66 ± 10 0.193 Encephalopathy 72% 37% 0.005 Ascite 85% 84% 0.647 WBCs (cells/IL) 8750 ± 5005 5672 ± 2734 0.002 Neutrophil (cells/IL) 105056 ± 80901 91000 ± 42063 0.361 Serum BUN (mmol/L) 8.8 ± 5.2 7.4 ± 5.9 0.282 Serum BUN (mmol/L) 78 ± 106 56 ± 38 0.350 ALT (IU/L) 78 ± 106 56 ± 38 0.350 ALT (IU/L) 43 ± 55 40 ± 55 0.803 Total bilirubin (mg/L) 102 ± 137 43 ± 45 0.021 INR 1.91 ± 0.64 1.55 ± 0.36 0.005 Albumin (g/L) 25 ± 5 26 ± 5 0.579	Grade 2	33%	28%	0.609
Duration of stay (d) 12 ± 8 12 ± 6 0.766 3-month mortality 34% 3% 0.008 Vital signsBody temperature (°C) 38 ± 0.7 37 ± 0.5 0.008 Heart rate (beats/min) 97 ± 15 85 ± 18 0.025 Respiratory rate (breaths/min) 21 ± 4 20 ± 5 0.189 Systolic blood pressure (mm Hg) 108 ± 21 111 ± 20 0.393 Diastolic blood pressure (mm Hg) 62 ± 13 66 ± 10 0.193 Encephalopathy 72% 37% 0.002 Ascite 85% 84% 0.647 WBCs (cells/IL) 6430 ± 4456 3668 ± 2151 0.001 Platelet (cells/IL) 105056 ± 80901 91000 ± 42063 0.361 Serum BUN (mmol/L) 8.8 ± 5.2 7.4 ± 5.9 0.282 Serum creatinine (μ mol/L) 116 ± 101 90 ± 51 0.167 AST (IU/L) 78 ± 106 56 ± 38 0.350 ALT (IU/L) 43 ± 55 40 ± 55 0.803 Total bilirubin (mg/L) 102 ± 137 43 ± 45 0.021 PT (%) 48 ± 18 58 ± 16 0.007 INR 1.91 ± 0.64 1.55 ± 0.36 0.005 Albumin (g/L) 25 ± 5 26 ± 5 0.579	Grade 3	34%	34%	0.952
3-month mortality 34% 3% 0.008 Vital signsBody temperature (°C) 38 ± 0.7 37 ± 0.5 0.008 Heart rate (beats/min) 97 ± 15 85 ± 18 0.025 Respiratory rate (breaths/min) 21 ± 4 20 ± 5 0.189 Systolic blood pressure (mm Hg) 108 ± 21 111 ± 20 0.393 Diastolic blood pressure (mm Hg) 62 ± 13 66 ± 10 0.193 Encephalopathy 72% 37% 0.005 Ascite 85% 84% 0.647 WBCs (cells/IL) 6430 ± 4456 3668 ± 2151 0.001 Platelet (cells/IL) 105056 ± 80901 91000 ± 42063 0.361 Serum BUN (mmol/L) 8.8 ± 5.2 7.4 ± 5.9 0.282 Serum creatinine (μ mol/L) 116 ± 101 90 ± 51 0.167 AST (IU/L) 78 ± 106 56 ± 38 0.350 ALT (IU/L) 43 ± 55 40 ± 55 0.803 Total bilirubin (mg/L) 102 ± 137 43 ± 45 0.021 INR 1.91 ± 0.64 1.55 ± 0.36 0.005 Albumin (g/L) 25 ± 5 26 ± 5 0.579	Duration of stay (d)	12 ± 8	12 ± 6	0.766
Vital signsBody temperature (°C) 38 ± 0.7 37 ± 0.5 0.008 Heart rate (beats/min) 97 ± 15 85 ± 18 0.025 Respiratory rate (breaths/min) 21 ± 4 20 ± 5 0.189 Systolic blood pressure (mm Hg) 108 ± 21 111 ± 20 0.393 Diastolic blood pressure (mm Hg) 62 ± 13 66 ± 10 0.193 Encephalopathy 72% 37% 0.005 Ascite 85% 84% 0.647 WBCs (cells/IL) 6430 ± 4456 3668 ± 2151 0.001 Platelet (cells/IL) 105056 ± 80901 91000 ± 42063 0.361 Serum BUN (mmol/L) 8.8 ± 5.2 7.4 ± 5.9 0.282 Serum BUN (mmol/L) 116 ± 101 90 ± 51 0.167 AST (IU/L) 78 ± 106 56 ± 38 0.350 ALT (IU/L) 43 ± 55 40 ± 55 0.803 Total bilirubin (mg/L) 102 ± 137 43 ± 45 0.021 INR 1.91 ± 0.64 1.55 ± 0.36 0.005 Albumin (g/L) 25 ± 5 26 ± 5 0.579	3-month mortality	34%	3%	0.008
Body temperature (°C) 38 ± 0.7 37 ± 0.5 0.008 Heart rate (beats/min) 97 ± 15 85 ± 18 0.025 Respiratory rate (breaths/min) 21 ± 4 20 ± 5 0.189 Systolic blood pressure (mm Hg) 108 ± 21 111 ± 20 0.393 Diastolic blood pressure (mm Hg) 62 ± 13 66 ± 10 0.193 Encephalopathy 72% 37% 0.005 Ascite 85% 84% 0.647 WBCs (cells/IL) 8750 ± 5005 5672 ± 2734 0.002 Neutrophil (cells/IL) 6430 ± 4456 3668 ± 2151 0.001 Platelet (cells/IL) 105056 ± 80901 91000 ± 42063 0.361 Serum BUN (mmol/L) 8.8 ± 5.2 7.4 ± 5.9 0.282 Serum creatinine (μ mol/L) 116 ± 101 90 ± 51 0.167 AST (IU/L) 78 ± 106 56 ± 38 0.350 ALT (IU/L) 43 ± 55 40 ± 55 0.803 Total bilirubin (mg/L) 102 ± 137 43 ± 45 0.021 PT (%) 48 ± 18 58 ± 16 0.007 INR 1.91 ± 0.64 1.55 ± 0.36 0.005 Albumin (g/L) 25 ± 5 26 ± 5 0.579	Vital signs			
Heart rate (beats/min) 97 ± 15 85 ± 18 0.025 Respiratory rate (breaths/min) 21 ± 4 20 ± 5 0.189 Systolic blood pressure (mm Hg) 108 ± 21 111 ± 20 0.393 Diastolic blood pressure (mm Hg) 62 ± 13 66 ± 10 0.193 Encephalopathy 72% 37% 0.005 Ascite 85% 84% 0.647 WBCs (cells/IL) 8750 ± 5005 5672 ± 2734 0.002 Neutrophil (cells/IL) 6430 ± 4456 3668 ± 2151 0.001 Platelet (cells/IL) 105056 ± 80901 91000 ± 42063 0.361 Serum BUN (mmol/L) 8.8 ± 5.2 7.4 ± 5.9 0.282 Serum reatinine (µmol/L) 116 ± 101 90 ± 51 0.167 AST (IU/L) 78 ± 106 56 ± 38 0.350 ALT (IU/L) 43 ± 55 40 ± 55 0.803 Total bilirubin (mg/L) 102 ± 137 43 ± 45 0.021 PT (%) 48 ± 18 58 ± 16 0.007 INR 1.91 ± 0.64 1.55 ± 0.36 0.005 Albumin (g/L) 25 ± 5 26 ± 5 0.579	Body temperature (°C)	38 ± 0.7	37 ± 0.5	0.008
Respiratory rate (breaths/min) 21 ± 4 20 ± 5 0.189 Systolic blood pressure (mm Hg) 108 ± 21 111 ± 20 0.393 Diastolic blood pressure (mm Hg) 62 ± 13 66 ± 10 0.193 Encephalopathy 72% 37% 0.005 Ascite 85% 84% 0.647 WBCs (cells/lL) 8750 ± 5005 5672 ± 2734 0.002 Neutrophil (cells/lL) 6430 ± 4456 3668 ± 2151 0.001 Platelet (cells/lL) 105056 ± 80901 91000 ± 42063 0.361 Serum BUN (mmol/L) 8.8 ± 5.2 7.4 ± 5.9 0.282 Serum creatinine 	Heart rate (beats/min)	97 ± 15	85 ± 18	0.025
Systolic blood pressure (mm Hg) 108 ± 21 111 ± 20 0.393 Diastolic blood pressure (mm Hg) 62 ± 13 66 ± 10 0.193 Encephalopathy 72% 37% 0.005 Ascite 85% 84% 0.647 WBCs (cells/IL) 8750 ± 5005 5672 ± 2734 0.002 Neutrophil (cells/IL) 6430 ± 4456 3668 ± 2151 0.001 Platelet (cells/IL) 105056 ± 80901 91000 ± 42063 0.361 Serum BUN (mmol/L) 8.8 ± 5.2 7.4 ± 5.9 0.282 Serum creatinine (μ mol/L) 116 ± 101 90 ± 51 0.167 AST (IU/L) 78 ± 106 56 ± 38 0.350 ALT (IU/L) 43 ± 55 40 ± 55 0.803 Total bilirubin 	Respiratory rate (breaths/min)	21 ± 4	20 ± 5	0.189
Diastolic blood pressure (mm Hg) 62 ± 13 66 ± 10 0.193 Encephalopathy 72% 37% 0.005 Ascite 85% 84% 0.647 WBCs (cells/IL) 8750 ± 5005 5672 ± 2734 0.002 Neutrophil (cells/IL) 6430 ± 4456 3668 ± 2151 0.001 Platelet (cells/IL) 105056 ± 80901 91000 ± 42063 0.361 Serum BUN (mmol/L) 8.8 ± 5.2 7.4 ± 5.9 0.282 Serum creatinine (μ mol/L) 116 ± 101 90 ± 51 0.167 AST (IU/L) 78 ± 106 56 ± 38 0.350 ALT (IU/L) 43 ± 55 40 ± 55 0.803 Total bilirubin (mg/L) 102 ± 137 43 ± 45 0.021 PT (%) 48 ± 18 58 ± 16 0.007 INR 1.91 ± 0.64 1.55 ± 0.366 0.005 Albumin (g/L) 25 ± 5 26 ± 5 0.579	Systolic blood pressure (mm Hg)	108 ± 21	111 ± 20	0.393
Encephalopathy72%37%0.005Ascite85%84%0.647WBCs (cells/lL)8750 \pm 50055672 \pm 27340.002Neutrophil (cells/lL)6430 \pm 44563668 \pm 21510.001Platelet (cells/lL)105056 \pm 8090191000 \pm 420630.361Serum BUN (mmol/L) 8.8 ± 5.2 7.4 ± 5.9 0.282Serum creatinine (μ mol/L)116 \pm 10190 \pm 510.167AST (IU/L)78 \pm 10656 \pm 380.350ALT (IU/L)43 \pm 5540 \pm 550.803Total bilirubin (mg/L)102 \pm 13743 \pm 450.021PT (%)48 \pm 1858 \pm 160.007INR1.91 \pm 0.641.55 \pm 0.3660.005Albumin (g/L)25 \pm 526 \pm 50.579	Diastolic blood pressure (mm Hg)	62 ± 13	66 ± 10	0.193
Ascite 85% 84% 0.647 WBCs (cells/IL) 8750 ± 5005 5672 ± 2734 0.002 Neutrophil (cells/IL) 6430 ± 4456 3668 ± 2151 0.001 Platelet (cells/IL) 105056 ± 80901 91000 ± 42063 0.361 Serum BUN (mmol/L) 8.8 ± 5.2 7.4 ± 5.9 0.282 Serum creatinine (µmol/L) 116 ± 101 90 ± 51 0.167 AST (IU/L) 78 ± 106 56 ± 38 0.350 ALT (IU/L) 43 ± 55 40 ± 55 0.803 Total bilirubin (mg/L) 102 ± 137 43 ± 45 0.021 PT (%) 48 ± 18 58 ± 16 0.007 INR 1.91 ± 0.64 1.55 ± 0.366 0.005 Albumin (g/L) 25 ± 5 26 ± 5 0.579	Encephalopathy	72%	37%	0.005
WBCs (cells/lL) 8750 ± 5005 5672 ± 2734 0.002 Neutrophil (cells/lL) 6430 ± 4456 3668 ± 2151 0.001 Platelet (cells/lL) 105056 ± 80901 91000 ± 42063 0.361 Serum BUN (mmol/L) 8.8 ± 5.2 7.4 ± 5.9 0.282 Serum creatinine (µmol/L) 116 ± 101 90 ± 51 0.167 AST (IU/L) 78 ± 106 56 ± 38 0.350 ALT (IU/L) 43 ± 55 40 ± 55 0.803 Total bilirubin (mg/L) 102 ± 137 43 ± 45 0.021 PT (%) 48 ± 18 58 ± 16 0.007 INR 1.91 ± 0.64 1.55 ± 0.366 0.005 Albumin (g/L) 25 ± 5 26 ± 5 0.579	Ascite	85%	84%	0.647
Neutrophil (cells/IL) 6430 ± 4456 3668 ± 2151 0.001 Platelet (cells/IL) 105056 ± 80901 91000 ± 42063 0.361 Serum BUN (mmol/L) 8.8 ± 5.2 7.4 ± 5.9 0.282 Serum creatinine (µmol/L) 116 ± 101 90 ± 51 0.167 AST (IU/L) 78 ± 106 56 ± 38 0.350 ALT (IU/L) 43 ± 55 40 ± 55 0.803 Total bilirubin (mg/L) 102 ± 137 43 ± 45 0.021 PT (%) 48 ± 18 58 ± 16 0.007 INR 1.91 ± 0.64 1.55 ± 0.366 0.005 Albumin (g/L) 25 ± 5 26 ± 5 0.579	WBCs (cells/lL)	8750 ± 5005	5672 ± 2734	0.002
Platelet (cells/lL) 105056 ± 80901 91000 ± 42063 0.361 Serum BUN (mmol/L) 8.8 ± 5.2 7.4 ± 5.9 0.282 Serum creatinine (µmol/L) 116 ± 101 90 ± 51 0.167 AST (IU/L) 78 ± 106 56 ± 38 0.350 ALT (IU/L) 78 ± 106 56 ± 38 0.303 Total bilirubin (mg/L) 102 ± 137 43 ± 45 0.021 PT (%) 48 ± 18 58 ± 16 0.007 INR 1.91 ± 0.64 1.55 ± 0.36 0.005 Albumin (g/L) 25 ± 5 26 ± 5 0.579	Neutrophil (cells/lL)	6430 ± 4456	3668 ± 2151	0.001
Serum BUN (mmol/L) 8.8 ± 5.2 7.4 ± 5.9 0.282 Serum creatinine (µmol/L) 116 ± 101 90 ± 51 0.167 AST (IU/L) 78 ± 106 56 ± 38 0.350 ALT (IU/L) 43 ± 55 40 ± 55 0.803 Total bilirubin (mg/L) 102 ± 137 43 ± 45 0.021 PT (%) 48 ± 18 58 ± 16 0.007 INR 1.91 ± 0.64 1.55 ± 0.36 0.005 Albumin (g/L) 25 ± 5 26 ± 5 0.579	Platelet (cells/lL)	105056 ± 80901	91000 ± 42063	0.361
Serum creatinine (μ mol/L)116 ± 10190 ± 510.167AST (IU/L)78 ± 10656 ± 380.350ALT (IU/L)43 ± 5540 ± 550.803Total bilirubin (mg/L)102 ± 13743 ± 450.021PT (%)48 ± 1858 ± 160.007INR1.91 ± 0.641.55 ± 0.360.005Albumin (g/L)25 ± 526 ± 50.579	Serum BUN (mmol/L)	8.8 ± 5.2	7.4 ± 5.9	0.282
AST (IU/L) 78 ± 106 56 ± 38 0.350 ALT (IU/L) 43 ± 55 40 ± 55 0.803 Total bilirubin (mg/L) 102 ± 137 43 ± 45 0.021 PT (%) 48 ± 18 58 ± 16 0.007 INR 1.91 ± 0.64 1.55 ± 0.36 0.005 Albumin (g/L) 25 ± 5 26 ± 5 0.579	Serum creatinine (µmol/L)	116 ± 101	90 ± 51	0.167
ALT (IU/L) 43 ± 55 40 ± 55 0.803 Total bilirubin (mg/L) 102 ± 137 43 ± 45 0.021 PT (%) 48 ± 18 58 ± 16 0.007 INR 1.91 ± 0.64 1.55 ± 0.36 0.005 Albumin (g/L) 25 ± 5 26 ± 5 0.579	AST (IU/L)	78 ± 106	56 ± 38	0.350
Total bilirubin (mg/L) 102 ± 137 43 ± 45 0.021 PT (%) 48 ± 18 58 ± 16 0.007 INR 1.91 ± 0.64 1.55 ± 0.36 0.005 Albumin (g/L) 25 ± 5 26 ± 5 0.579	ALT (IU/L)	43 ± 55	40 ± 55	0.803
PT (%) 48 ± 18 58 ± 16 0.007 INR 1.91 ± 0.64 1.55 ± 0.36 0.005 Albumin (g/L) 25 ± 5 26 ± 5 0.579	Total bilirubin (mg/L)	102 ± 137	43 ± 45	0.021
INR 1.91 ± 0.64 1.55 ± 0.36 0.005 Albumin (g/L) 25 ± 5 26 ± 5 0.579	PT (%)	48 ± 18	58 ± 16	0.007
Albumin (g/L) 25 ± 5 26 ± 5 0.579	INR	1.91 ± 0.64	1.55 ± 0.36	0.005
-	Albumin (g/L)	25 ± 5	26 ± 5	0.579

 TABLE 2: Clinical and laboratory variables associated with infection on admission.

TABLE 2: Continued.

	Bacterial infection group n = 60	Nonbacterial infection group n = 32	<i>p</i> value
Serum sodium	132 ± 5	134 ± 4	0.177
CRP (mg/L)	46 ± 44.5	19.61 ± 24.95	<.001
PCT (ng/mL)	1.84 ± 4.07	0.20 ± 0.48	<.001

ALT: alanine aminotransferase; AST: aspartate aminotransferase; CRP: C-reactive protein; PCT: procalcitonin; INR: international normalized ratio; WBC: white blood cell; PT: prothrombin time; MELD: Model for End-Stage Liver Disease; APACHE II: Acute Physiology and Chronic Health Disease Classification System II; BUR: blood urea nitrogen; CLIF-SOFA: chronic liver failure-sequential organ failure assessment; ACLF: Acute-on-chronic liver failure.

 TABLE 3: Univariate and multivariate analysis of factors associated with bacterial infection.

	Bacterial infection diagnosis	
	Univariate	Multivariate
	analysis	analysis
Age > 60 years	0.609	0.285
Gender	0.775	0.399
Tabagism	0.35	0.376
Alcoholism	0.786	0.076
Diabetes mellitus	0.614	0.75
Hypertension	0.231	0.535
Duration of cirrhosis	0.170	0.473
Length of hospitalization	0.291	0.843
Child-Pugh score	0.311	0.199
MELD score > 15	0.001	0.022
Ascite	0.937	0.744
Encephalopathy	0.001	0.021
WBC \geq 6635 cells/lL	0.005	0.22
$CRP \ge 20 \text{ mg/L}$	0.000	0.184
$PCT \ge 0.5 \text{ ng/mL}$	0.000	0.009

WBC: white blood cells; CRP: C-reactive protein; PCT: procalcitonin; MELD: Model for End-Stage Liver Disease.

encephalopathy, and PCT \geq 0.5were significantly correlated to BI (Table 3). We evaluated the effectiveness of WBC, PCT, and CRP measurements in predicting infection in decompensated cirrhosis using the assessment of ROC curves. The area under the curve (AUC), sensitivity, specificity, positive and negative predictive values, and suggested cutoff values for each marker are summarized in Table 4. ROC analysis of CRP serum level showed the slightly higher AUC (0.745). PCT was more specific (96.6% vs. 75%) whereas CRP was more sensitive (70 vs. 45%).

3.1. *Three-Month Mortality*. Three-month mortality rate was 27%. Patients in the BI group had higher 3-month mortality rate (34% vs. 3%, p = 0.008) than those in the NBI group. However, multivariate risk factor analysis indicated that BI

TABLE 4: The results of ROC curve analysis for bacterial infection diagnosis.

	AUC (95% CI)	Р	Suggested cutoff	Sensitivity (%)	Specificity (%)	PPV (%)	NPV (%)
WBC	0.694 (IC 95%: 0.585-0.803)	0.002	6635	65	65.5	78	50
CRP	0.745 (IC 95%: 0.635-0.855)	<.001	20	70	75	84	57
PCT	0.741 (IC 95%: 0.639-0.843)	<.001	0.5	45	96.6	97.5	59

WBC: white blood cells. CRP: C-reactive protein; PCT: procalcitonin; PPV: positive predictive value; NPV: negative predictive value.

TABLE 5: Univariate and multivariate analysis of factors associated with 3-month mortality in admitted patients with decompensated liver cirrhosis.

	Univariate analysis	Multivariate analysis
Child-Pugh (class)	0.006	0.007
Encephalopathy	0.013	0.005
Infection	0.001	0.485
Heart rate	0.005	0.092
Temperature	0.055	0.547
WBC	0.001	0.331
Neutrophil count	< 0.001	0.155
Platelets	< 0.001	0.490
PT %	0.029	0.321
INR	0.036	0.962
CRP	0.001	0.053
РСТ	0.018	< 0.001
Serum creatinine	0.014	< 0.001
AST	0.095	< 0.001
Child-Pugh (score)	0.009	0.006
MELD	< 0.001	0.091

WBC: white blood cells; INR: international normalized ratio; CRP: C-reactive protein; PT: prothrombin time; PCT: procalcitonin; AST: aspartate aminotransferase; MELD: Model for End-Stage Liver Disease.

was not an independent 3-month mortality risk factor (Table 5). PCT serum level was significantly associated with 3-month mortality (p < 0.001). ROC analysis of PCT serum level showed the AUC of 0.735 (CI 95%: 0.576-0.895). Suggested cutoff was 0.5 ng/mL; sensitivity, specificity, positive predictive value, and negative predictive value were, respectively, 66.7%, 77.6%, 59%, and 82% (Figure 1). In the BI group, deceased patients were more often Child-Pugh class C and had lower temperature on admission, higher Child-Pugh score, higher leukocyte, neutrophil, and platelet counts, lower prothrombin time, and higher serum CRP, PCT, and creatinine levels (Table 6). In multivariate logistic regression mode, CP class C, lower temperature on admission, higher CP score, and higher platelet count were retained as predictors' parameters for three-month mortality (Table 7).

4. Discussion

In our study, the high rate of BI among patients with decompensated cirrhosis can be explained by the advanced liver failure observed in these patients. Our results showed that PCT and CRP serum levels were significantly higher in the



FIGURE 1: ROC curves for procalcitonin (PCT), C-reactive protein (CRP), and white blood cells (WBC) in predicting 3-month mortality.

BI group, and thus, these markers were useful in the diagnosis of BI in decompensated cirrhosis. Although they are mainly produced by the liver, hepatic insufficiency does not affect their diagnostic accuracy [8]. That is explained by a maintained hepatic production [9-11] and/or an extrahepatic production [12-15] of those two biomarkers during cirrhosis. On the other side, WBC count is deeply influenced by hypersplenism even if their production may be maintained. That can explain the less BI diagnosis accuracy of WBC observed in our study. Several studies have shown the reliability of PCT and CRP for the diagnosis of infection during cirrhosis with important AUC. In a recent meta-analysis including 1144 patients with liver cirrhosis, AUC for PCT and CRP was, respectively, 0.92 (95% CI: 0.89-0.94) and 0.87 (95% Cl: 0.84-0.90) [16]. This is probably due to differences in demographic characteristics and cirrhosis severity observed in our population. The cutoffs used are also different from ours. In the present study, diagnostic accuracy of CRP and PCT was comparable but it is still relatively low. That is why we think that PCT and CRP cannot be used alone to either confirm or exclude BI diagnosis. We found that,

	Surviving	Deceased	t value
Say	16/21	9/14	<i>p</i> value
Child Durch (class)	10/21	9/14	0.164
Cillid-Pugil (class)	00/	294	0.425
A	0%	3%	0.427
В	4%	43%	0.001
С	96%	54%	0.001
Child-Pugh score	10 ± 2	11 ± 1	0.004
Respiratory rate	21 ± 3	21 ± 4	0.720
Temperature	38 ± 0.8	37 ± 0.6	0.004
WBC (cells/lL)	7632 ± 3651	10549 ± 6314	0.027
Neutrophil count (cells/lL)	5369 ± 3049	8137 ± 5771	0.018
Platelets (cells/lL)	83659 ± 66387	139478 ± 91280	0.008
PT (%)	51 ± 19	41 ± 13	0.031
CRP (mg/L)	37 ± 29	61 ± 60	0.041
PCT (ng/mL)	$1.21 \pm 2 \pm 88$	2.84 ± 5.39	0.131
Creatinine (µmol/L)	96 ± 63	150 ± 139	0.045
AST (IU/L)	63 ± 44	91 ± 162	0.396
MELD	18 ± 7	23 ± 6	0.005

TABLE 6: Clinical and laboratory variables associated with 3-month mortality in the BI group.

PT: prothrombin time; WBC: white blood cells; CRP: C-reactive protein; PCT: procalcitonin; AST: aspartate aminotransferase; MELD: Model for End-Stage Liver Disease.

TABLE 7: Univariate and multivariate analysis of factors associated with 3-month mortality in the BI group.

Variable	Univariate analysis	Multivariate analysis
Sex	0.184	0.900
Child-Pugh (class)		
В	< 0.001	0.887
С	< 0.001	< 0.001
Child-Pugh (score)	0.004	0.627
Respiratory rate	0.720	0.111
Temperature	0.004	0.01
WBC	0.027	0.131
Neutrophil count	0.018	0.075
Platelets	0.008	0.018
Prothrombin time	0.031	0.874
CRP	0.041	0.225
РСТ	0.131	0.318
Serum creatinine	0.045	0.197
AST	0.396	0.300
MELD score	0.005	0.411

WBC: white blood cells; CRP: C-reactive protein; PCT: procalcitonin; AST: aspartate aminotransferase; MELD: Model for End-Stage Liver Disease.

for the diagnosis of BI, CRP was more sensitive (70% vs. 45%) while PCT was more specific (96.9% vs. 75%). Similar results were reported by Lin et al.: CRP sensitivity was higher (87% vs. 79%) while PCT was more specific (89% vs. 85%) [16]. In addition, the CRP had a more discriminative value in the Papp study [17]. In order to enhance the diagnostic performance of CRP and PCT, the

use of an algorithm that integrates clinical data with PCT or CRP can be helpful. In addition, it may be interesting to study the usefulness of an algorithm combing CRP and PCT.

4.1. Mortality. We have reconfirmed the gravity of BI in cirrhotics as already attested [18]. Three-month mortality was twelve times higher in infected patients compared to noninfected patients (34% vs. 3%, p = 0.08). However, multivariate risk factor analysis indicated that BI was not an independent 3-month mortality risk factor. Lazzarotto et al. did not find any association between infection at admission and death before the seventh day of hospitalization [19]. In Khot et al. study, sepsis was not objectively an independent predictor of mortality [20]. In our study, only serum PCT level was significantly related to 3-month mortality. The relationship between PCT and CRP levels and mortality reported in previous studies was contradictory [19, 21–23]. However, in the BI group, PCT and CRP did not show any prognostic value. That can be explained by the high severity of cirrhosis in the NBI group. In fact, the CP score influenced death.

Our study has limitations. It is a monocentric study with a relatively small number of patients. In addition, PCT measurement was performed on admission regardless of the presence or the absence of infection.

5. Conclusion

Regarding BI in patients with decompensated cirrhosis, CRP maintains efficiency slightly higher than that of the PCT without being discriminative. However, no prognostic value has been established for these markers. In order to improve

the diagnosis and reliability of prognosis, it may be interesting to combine them with each other or with other biological and/or clinical parameters.

Abbreviations

ACLF:	Acute-on-chronic liver failure
ALL:	Alanine aminotransferase
APACHE II:	Acute Physiology and Chronic Health Disease
	Classification System II
AST:	Aspartate aminotransferase
BI:	Bacterial infection (group)
CP:	Child-Turcotte-Pugh
CLIF-SOFA:	Chronic liver failure-sequential organ failure
	assessment
CRP:	C-reactive protein
INR:	International normalized ratio
MELD:	Model for End-Stage Liver Disease
NBI:	Nonbacterial infection (group)
NPV:	Negative predictive value
PCT:	Procalcitonin
PPV:	Positive predictive value
PT:	Prothrombin time
WBC:	White blood cells.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Disclosure

Our study is within the scientific research framework of the Faculty of Medicine of Tunis.

Conflicts of Interest

We have no conflict of interest.

References

- T. Gustot, F. Durand, D. Lebrec, J. L. Vincent, and R. Moreau, "Severe sepsis in cirrhosis," *Hepatology*, vol. 50, no. 6, pp. 2022–2033, 2009.
- [2] S. Ben-Eliyahu, G. G. Page, R. Yirmiya, and A. N. Taylor, "Acute alcohol intoxication suppresses natural killer cell activity and promotes tumor metastasis," *Nature Medicine*, vol. 2, no. 4, pp. 457–460, 1996.
- [3] M. Navasa, J. Fernandez, and J. Rodes, "Bacterial infections in liver cirrhosis," *Italian Journal of Gastroenterology and Hepatology*, vol. 31, no. 7, pp. 616–625, 1999.
- [4] W. A. Knaus, E. A. Draper, D. P. Wagner, and J. E. Zimmerman, "APACHE II: a severity of disease classification system," *Critical Care Medicine*, vol. 13, no. 10, pp. 818–829, 1985.
- [5] R. N. H. Pugh, I. M. Murray-Lyon, J. L. Dawson, M. C. Pietroni, and R. Williams, "Transection of the oesophagus for bleeding oesophageal varices," *The British Journal of Surgery*, vol. 60, no. 8, pp. 646–649, 1973.

- [6] P. S. Kamath, R. H. Wiesner, M. Malinchoc et al., "A model to predict survival in patients with end-stage liver disease," *Hepatology*, vol. 33, no. 2, pp. 464–470, 2001.
- [7] R. Moreau, R. Jalan, P. Gines et al., "Acute-on- chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis," *Gastroenterology*, vol. 144, no. 7, pp. 1426–1437.e9, 2013.
- [8] D. P. Bota, M. Van Nuffelen, A. N. Zakariah, and J.-L. Vincent, "Serum levels of C- reactive protein and procalcitonin in critically ill patients with cirrhosis of the liver," *The Journal of Laboratory and Clinical Medicine*, vol. 146, no. 6, pp. 347– 351, 2005.
- [9] B. Campillo, E. Sherman, J. Richardet, and P. Bories, "Serum leptin levels in alcoholic liver cirrhosis: relationship with gender, nutritional status, liver function and energy metabolism," *European Journal of Clinical Nutrition*, vol. 55, no. 11, pp. 980– 988, 2001.
- [10] H. Tilg, A. Wilmer, W. Vogel et al., "Serum levels of cytokines in chronic liver diseases," *Gastroenterology*, vol. 103, no. 1, pp. 264–274, 1992.
- [11] R. Meliconi, O. Parracino, A. Facchini et al., "Acute phase proteins in chronic and malignant liver diseases," *Liver*, vol. 8, no. 2, pp. 65–74, 1988.
- [12] P. Calabró, J. T. Willerson, and E. T. H. Yeh, "Inflammatory cytokines stimulated C- reactive protein production by human coronary artery smooth muscle cells," *Circulation*, vol. 108, no. 16, pp. 1930–1932, 2003.
- [13] W. J. Jabs, B. A. Lögering, P. Gerke et al., "The kidney as a second site of human C-reactive protein formation in vivo," *European Journal of Immunology*, vol. 33, no. 1, pp. 152–161, 2003.
- [14] K. Yasojima, C. Schwab, E. G. McGeer, and P. L. McGeer, "Human neurons generate C-reactive protein and amyloid P: upregulation in Alzheimer's disease," *Brain Research*, vol. 887, no. 1, pp. 80–89, 2000.
- [15] Q. Dong and J. R. Wright, "Expression of C-reactive protein by alveolar macrophages," *Journal of Immunology*, vol. 156, no. 12, pp. 4815–4820, 1996.
- [16] K.-H. Lin, F.-L. Wang, M.-S. Wu et al., "Serum procalcitonin and C-reactive protein levels as markers of bacterial infection in patients with liver cirrhosis: a systematic review and metaanalysis," *Diagnostic Microbiology and Infectious Disease*, vol. 80, no. 1, pp. 72–78, 2014.
- [17] M. Papp, Z. Vitalis, I. Altorjay et al., "Acute phase proteins in the diagnosis and prediction of cirrhosis associated bacterial infections," *Liver International*, vol. 32, no. 4, pp. 603– 611, 2012.
- [18] M. Borzio, F. Salerno, L. Piantoni et al., "Bacterial infection in patients with advanced cirrhosis: a multicentre prospective study," *Digestive and Liver Disease*, vol. 33, no. 1, pp. 41–48, 2001.
- [19] C. Lazzarotto, M. F. Ronsoni, L. Fayad et al., "Acute phase proteins for the diagnosis of bacterial infection and prediction of mortality in acute complications of cirrhosis," *Annals of Hepatology*, vol. 12, no. 4, pp. 599–607, 2013.
- [20] A. A. Khot, P. Somani, P. Rathi, and A. Amarapurkar, "Prognostic factors in acute-on-chronic liver failure: a prospective study from western India," *Indian Journal of Gastroenterology*, vol. 33, no. 2, pp. 119–124, 2014.
- [21] J. P. Cervoni, À. Amorós, R. Bañares et al., "Prognostic value of C-reactive protein in patients with cirrhosis:

external validation from the Canonic cohort," *European Journal of Gastroenterology & Hepatology*, vol. 28, no. 9, pp. 1028–1034, 2016.

- [22] S. Chirapongsathorn, W. Bunraksa, A. Chaiprasert, D. Punpanich, O. Supasyndh, and P. S. Kamath, "Adding C-reactive protein and procalcitonin to the model of endstage liver disease score improves mortality prediction in patients with complications of cirrhosis," *Journal of Gastroenterology and Hepatology*, vol. 33, no. 3, pp. 726–732, 2018.
- [23] J. U. Jensen, L. Heslet, T. H. Jensen, K. Espersen, P. Steffensen, and M. Tvede, "Procalcitonin increase in early identification of critically ill patients at high risk of mortality," *Critical Care Medicine*, vol. 34, no. 10, pp. 2596–2602, 2006.



The Scientific World Journal

Journal of Immunology Research



Research and Practice











BioMed Research International



PPAR Research

Journal of Ophthalmology



Computational and Mathematical Methods in Medicine



International



Behavioural Neurology



Evidence-Based Complementary and Alternative Medicine







Research and Treatment





Oxidative Medicine and Cellular Longevity



Submit your manuscripts at www.hindawi.com